032300.Kq
032300.KQ is a pharmaceutical company that generates revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
Business. 032300.KQ is a pharmaceutical company that generates revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
032300.KQ is a pharmaceutical company that generates revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
The company's capital structure is characterized by a debt-to-equity ratio of 0.57, indicating a moderate reliance on debt financing relative to equity. Liquidity is assessed as medium, with a current ratio of 1.14, suggesting the company has just enough current assets to cover its current liabilities. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.
Profitability metrics show a return on equity of -3.84% and a return on assets of -2.08%, both of which are negative and significantly below the industry norms for pharmaceutical companies. These figures indicate that the company is not generating returns that meet the cost of capital or asset utilization expectations, which could be a concern for investors and stakeholders.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher risks from market-specific downturns or regulatory changes in its primary operating region.
Looking ahead, the company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year. However, the negative operating and net income figures suggest that the company is currently not growing profitably and may require strategic interventions to improve its financial performance.
Risk factors include the company's negative net cash position and the potential for liquidity constraints, which could affect its ability to fund operations and invest in growth opportunities. The risk of dilution is assessed as low, with no significant dilution potential identified in the basic shares outstanding. However, the company's negative free cash flow and capital expenditures suggest that it may need to raise additional capital in the future, which could lead to dilution.
Recent events, as disclosed in the latest financial filings, include a decline in operating income and net income, which may be attributed to increased costs or reduced sales volumes. No specific events such as mergers, acquisitions, or regulatory changes are mentioned in the available data, but the company's financial performance indicates a need for strategic reassessment.
- The company has a moderate debt-to-equity ratio, but its liquidity position is only medium, with a current ratio of 1.14.
- Profitability is weak, with negative returns on equity and assets, indicating poor performance relative to industry standards.
- Revenue is not diversified across segments or geographies, increasing exposure to market-specific risks.
- The company is not currently growing profitably, and its financial performance suggests a need for strategic interventions.
- The risk of dilution is low, but the company's negative free cash flow and capital expenditures may necessitate future capital raising.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 032300.KQ Market data — financials · 2026-05-26